Final-Program-ATS-2023-AP.vp

280

TUESDAY • MAY 23

12:30 How Can Researchers Use ECHO’s Controlled Access Public Use Data Set in DASH? R. Rosen, PhD, Bethesda, MD 12:45 Panel Discussion C.J. Blaisdell, MD, North Bethesda, MD

ENVIRONMENTAL INFLUENCES ON CHILD HEALTH OUTCOMES (ECHO)/NIH OUTSIDE ORGANIZATION SESSION

L15 NIH ENVIRONMENTAL INFLUENCES ON CHILD HEALTH OUTCOMES (ECHO): NATIONAL LONGITUDINAL RESOURCE FOR CHILD LUNG HEALTH RESEARCHERS 12:00 PM - 1:00 PM Walter E. Washington Convention Center Room 202 B (Level 2) Target Audience Providers of maternal and child health; Providers of lung health; Researchers of Developmental Origins of Health and Development, Pediatric Pulmonologists; Environmental researchers and physicians Objectives At the conclusion of this session, the participant will be able to: • learn ECHO’s design to support developmental origins of health and disease research. • learn how ECHO data has supported innovative epidemiologic studies of the origins of asthma and early onset of health disparities. • learn the breadth and depth of available ECHO data from diverse participantsacross the nation spanning decades of data collection and how to access ECHO data from DASH for airways research. The NIH-supported Environmental Influences on Child Health Outcomes (ECHO) program supports multiple synergistic, longitudinal cohort studies across the U.S. to investigate how early environmental exposures—including physical, chemical, social, behavioral, biological, natural, and built environments—affect genetic susceptibility, child health and development. The multiple cohorts share protocol-specified data elements from ~100,000 participants and ~50,000 children, including bioassay data analyzed by the NIH Human Health Exposure Analysis Resource (HHEAR). A de-identified near anonymized data set is now available as a national resource for research. This session will focus on how the ECHO data repository can support child health research particularly relevant to the development of airway diseases and health. Chairing: C.J. Blaisdell, MD, North Bethesda, MD C.L.M. Joseph, PhD, Detroit, MI 12:00 ECHO as a National Resource for Lung Research M. Gillman, MD, SM, North Bethesda, MD 12:05 What have we learned from ECHO? Research from the Airways Group J. Gern, MD, Madison, WI 12:15 What is in ECHO’s Controlled Access Public Use Data Set, Now Available in the NICHD Data and Specimen Hub (DASH)? D. Catellier, PhD, Research Triangle, NC

DIVISION OF LUNG DISEASES, NHLBI/DLD OUTSIDE ORGANIZATION SESSION

L16 IMPACT OF SEX AND GENDER ON AUTOIMMUNE LUNG DISEASE 12:00 PM - 1:00 PM Walter E. Washington Convention Center Room 152 A-B (Street Level) Target Audience Basic scientists, physician-scientists, and healthcare providers with research interests related to the influence of sex and gender on autoimmune-associated lung diseases. Objectives At the conclusion of this session, the participant will be able to: • create awareness, interest, and increase knowledge of the influence of sex and gender on autoimmune lung disease research. • learn about innovative methods to eliminate gaps in the design, conduct, and analysis of sex and gender-related aspects of autoimmune lung disease research • clinical Phenotyping of autoimmune ILD and diagnose, predict and improve clinical outcomes by re-purposing existing drugs This session will highlight recent research advances involving the role of sex and gender in a number of autoimmune-related lung diseases, including systemic sclerosis-associated interstitial lung disease (SSc-ILD), rheumatoid arthritis-associated ILD (RA-ILD), systemic lupus erythematosus (SLE) pneumonitis/pleuritis, and interstitial pneumonia with autoimmune features (IPAF). Chairing: L.J. Vuga, MD, MPH, PhD, Bethesda, MD M.E. Lachowicz-Scroggins, PhD, Bethesda, MD 12:00 Influence of Sex/Gender on Scleroderma-Associated ILD E. Volkmann, MD, MSci, Los Angeles, CA 12:15 Sex/Gender Differences in Lung Inflammation and Rheumatoid Arthritis J.A. Sparks, MD, Boston, United States 12:30 Role of B Cells Pulmonary Fibrosis Resulting from STING Gain-of-Function Autoinflammation A. Marshak-Rothstein, PhD, Worcester, United States 12:45 The Influence of Sex/Gender on Treatment Effect in Interstitial Pneumonia with Autoimmune Features A.O. Adegunsoye, MD, MS, Chicago, IL

ATS 2023 • Washington, DC